Literature DB >> 30282831

A sheep model of cystic fibrosis generated by CRISPR/Cas9 disruption of the CFTR gene.

Zhiqiang Fan1, Iuri Viotti Perisse1, Calvin U Cotton2, Misha Regouski1, Qinggang Meng1, Chaim Domb2, Arnaud J Van Wettere1, Zhongde Wang1, Ann Harris3, Kenneth L White1, Irina A Polejaeva1.   

Abstract

Cystic fibrosis (CF) is a genetic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. The major cause of limited life span in CF patients is progressive lung disease. CF models have been generated in 4 species (mice, rats, ferrets, and pigs) to enhance our understanding of the CF pathogenesis. Sheep may be a particularly relevant animal to model CF in humans due to the similarities in lung anatomy and development in the two species. Here, we describe the generation of a sheep model for CF using CRISPR/Cas9 genome editing and somatic cell nuclear transfer (SCNT) techniques. We generated cells with CFTR gene disruption and used them for production of CFTR-/- and CFTR+/- lambs. The newborn CFTR-/- sheep developed severe disease consistent with CF pathology in humans. Of particular relevance were pancreatic fibrosis, intestinal obstruction, and absence of the vas deferens. Also, substantial liver and gallbladder disease may reflect CF liver disease that is evident in humans. The phenotype of CFTR-/- sheep suggests this large animal model will be a useful resource to advance the development of new CF therapeutics. Moreover, the generation of specific human CF disease-associated mutations in sheep may advance personalized medicine for this common genetic disorder.

Entities:  

Keywords:  Development; Genetic diseases; Genetics

Year:  2018        PMID: 30282831      PMCID: PMC6237476          DOI: 10.1172/jci.insight.123529

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  37 in total

1.  Viable offspring derived from fetal and adult mammalian cells.

Authors:  I Wilmut; A E Schnieke; J McWhir; A J Kind; K H Campbell
Journal:  Nature       Date:  1997-02-27       Impact factor: 49.962

Review 2.  Towards an ovine model of cystic fibrosis.

Authors:  A Harris
Journal:  Hum Mol Genet       Date:  1997-12       Impact factor: 6.150

3.  Cystic fibrosis of the pancreas: involvement of MUC6 mucin in obstruction of pancreatic ducts.

Authors:  C J Reid; K Hyde; S B Ho; A Harris
Journal:  Mol Med       Date:  1997-06       Impact factor: 6.354

4.  Pancreatic damage in fetal and newborn cystic fibrosis pigs involves the activation of inflammatory and remodeling pathways.

Authors:  Maisam Abu-El-Haija; Shyam Ramachandran; David K Meyerholz; Marwa Abu-El-Haija; Michelle Griffin; Radhamma L Giriyappa; David A Stoltz; Michael J Welsh; Paul B McCray; Aliye Uc
Journal:  Am J Pathol       Date:  2012-06-08       Impact factor: 4.307

5.  Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts.

Authors:  A E Schnieke; A J Kind; W A Ritchie; K Mycock; A R Scott; M Ritchie; I Wilmut; A Colman; K H Campbell
Journal:  Science       Date:  1997-12-19       Impact factor: 47.728

6.  Epidemiology of liver disease in cystic fibrosis: a longitudinal study.

Authors:  Thierry Lamireau; Sylvie Monnereau; Steven Martin; Jacques-Edouard Marcotte; Maria Winnock; Fernando Alvarez
Journal:  J Hepatol       Date:  2004-12       Impact factor: 25.083

7.  Increased pregnancy losses following serial somatic cell nuclear transfer in goats.

Authors:  Min Yang; Iuri Perisse; Zhiqiang Fan; Misha Regouski; Mirella Meyer-Ficca; Irina A Polejaeva
Journal:  Reprod Fertil Dev       Date:  2018-10       Impact factor: 2.311

8.  Evaluation of gene targeting by homologous recombination in ovine somatic cells.

Authors:  Sarah H Williams; Virender Sahota; Timea Palmai-Pallag; Scott J Tebbutt; Jean Walker; Ann Harris
Journal:  Mol Reprod Dev       Date:  2003-10       Impact factor: 2.609

9.  Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth.

Authors:  David A Stoltz; David K Meyerholz; Alejandro A Pezzulo; Shyam Ramachandran; Mark P Rogan; Greg J Davis; Robert A Hanfland; Chris Wohlford-Lenane; Cassie L Dohrn; Jennifer A Bartlett; George A Nelson; Eugene H Chang; Peter J Taft; Paula S Ludwig; Mira Estin; Emma E Hornick; Janice L Launspach; Melissa Samuel; Tatiana Rokhlina; Philip H Karp; Lynda S Ostedgaard; Aliye Uc; Timothy D Starner; Alexander R Horswill; Kim A Brogden; Randall S Prather; Sandra S Richter; Joel Shilyansky; Paul B McCray; Joseph Zabner; Michael J Welsh
Journal:  Sci Transl Med       Date:  2010-04-28       Impact factor: 17.956

10.  Expression of the cystic fibrosis gene in human development.

Authors:  A Harris; G Chalkley; S Goodman; L Coleman
Journal:  Development       Date:  1991-09       Impact factor: 6.868

View more
  28 in total

1.  Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.

Authors:  Yinghua Tang; Ziying Yan; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2020-04-15       Impact factor: 5.695

2.  Treating Cystic Fibrosis with mRNA and CRISPR.

Authors:  Alejandro Da Silva Sanchez; Kalina Paunovska; Ana Cristian; James E Dahlman
Journal:  Hum Gene Ther       Date:  2020-09-08       Impact factor: 5.695

3.  On the Process of Discovering Leads That Target the Heparin-Binding Site of Neutrophil Elastase in the Sputum of Cystic Fibrosis Patients.

Authors:  Shravan Morla; Nehru Viji Sankaranarayanan; Daniel K Afosah; Megh Kumar; Apparao B Kummarapurugu; Judith A Voynow; Umesh R Desai
Journal:  J Med Chem       Date:  2019-05-28       Impact factor: 7.446

Review 4.  Animal models of cystic fibrosis in the era of highly effective modulator therapies.

Authors:  Barbara R Grubb; Alessandra Livraghi-Butrico
Journal:  Curr Opin Pharmacol       Date:  2022-05-13       Impact factor: 4.768

Review 5.  CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.

Authors:  Garima Sharma; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee; Chiranjib Chakraborty
Journal:  Mol Ther       Date:  2020-09-20       Impact factor: 11.454

Review 6.  On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis.

Authors:  Marjolein Ensinck; Angélique Mottais; Claire Detry; Teresinha Leal; Marianne S Carlon
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

7.  Enhancing Cystic Fibrosis Immune Regulation.

Authors:  Anna M van Heeckeren; Morgan T Sutton; David R Fletcher; Craig A Hodges; Arnold I Caplan; Tracey L Bonfield
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

8.  Progress of genome editing technology and developmental biology useful for radiation research.

Authors:  Kento Miura; Atsuo Ogura; Kohei Kobatake; Hiroaki Honda; Osamu Kaminuma
Journal:  J Radiat Res       Date:  2021-05-05       Impact factor: 2.724

Review 9.  Human Molecular Genetics and the long road to treating cystic fibrosis.

Authors:  Ann Harris
Journal:  Hum Mol Genet       Date:  2021-10-01       Impact factor: 5.121

10.  Engineering bone phenotypes in domestic animals: Unique resources for enhancing musculoskeletal research.

Authors:  Larry J Suva; Mark E Westhusin; Charles R Long; Dana Gaddy
Journal:  Bone       Date:  2019-11-08       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.